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of the Creative Com
provided it is propeObjectives: To determine the incidence and risk factors of mortality for all HIV-infected
patients receiving antiretroviral treatment at public and private healthcare facilities in
the Botswana National HIV/AIDS Treatment Programme.
Design: We studied routinely collected data from 226 030 patients enrolled in the
Botswana National HIV/AIDS Treatment Programme from 2002 to 2013.
Methods: A person-years (P-Y) approach was used to analyse all-cause mortality and
follow-up rates for all HIV-infected individuals with documented antiretroviral therapy
initiation dates. Marginal structural modelling was utilized to determine the effect of
treatment on survival for those with documented drug regimens. Sensitivity analyses
were performed to assess the robustness of our results.
Results: Median follow-up time was 37 months (interquartile range 11–75). Mortality
was highest during the first 3 months after treatment initiation at 11.79 (95% confidence
interval 11.49–12.11) deaths per 100 P-Y, but dropped to 1.01 (95% confidence
interval 0.98–1.04) deaths per 100 P-Y after the first year of treatment. Twelve-month
mortality declined from 7 to 2% of initiates during 2002–2012. Tenofovir was
associated with lower mortality than stavudine and zidovudine.
Conclusion: The observed mortality rates have been declining over time; however,
mortality in the first year, particularly first 3 months of antiretroviral treatment, remains
a distinct problem. This analysis showed lower mortality with regimens containing
tenofovir compared with zidovudine and stavudine. CD4þ cell count less than
100 cells/ml, older age and being male were associated with higher odds of mortality.
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Botswana is one of the countries hardest hit with the HIV
pandemic [1]. To respond to this public health menace,
the Government of Botswana launched its nationalan School of Public Health, Boston, Massachuse
na, and dCenter for Disease Control and Preven
o Mansour Farahani, MD, MPH, ScD, Harvard S
hsph.harvard.edu
2015; revised: 21 August 2015; accepted: 18 S
.0000000000000921
pyright Q 2016 Wolters Kluwer Health, Inc. All righ
mons Attribution-NonCommercial-NoDerivatives 4.0
rly cited. The work cannot be changed in any way oantiretroviral therapy (ART) programme called ‘Masa’,
meaning ‘new dawn’ in Setswana. By the end of 2014,
the programme had expanded to more than 302 healthcare
facilities, and eligibility requirements had increased the
CD4þ threshold to 350 cells/ml. By December 2014, thetts, USA, bMinistry of Health, cUniversity of Botswana,
tion, Atlanta, Georgia, USA.
chool of Public Health, Boston, MA, USA.
eptember 2015.
ts reserved. This is an open-access article distributed under the terms
License, where it is permissible to download and share the work
r used commercially. 477
478 AIDS 2016, Vol 30 No 3number of patients ever initiated ART had reached
247 856, of which 229 133 were in the public sector [2].
Prior studies have shown the success of this programme in
Botswana [3,4]. However, these studies were hampered
by small sample sizes. An analysis of the routinely
collected patient data is needed to evaluate the
performance of the national programme over time.
This study builds on our prior work [5], by providing a
rigorous evaluation of 12 years of follow-up data for adult
patients in the Masa Programme. This analysis was
designed to evaluate rates of mortality, while identifying
potential risk factors for mortality, including clinical and
demographic factors.Methods
Data
We analysed a database of all available electronic records
routinely collected for 226 030 HIV-infected adults from
176 healthcare facilities enrolled in the Masa Programme
with a documented ART initiation date. Once eligible
for ART, data are collected through a patient information
management system (PIMS) developed by the Ministry of
Health (MOH) in Microsoft Access, or in nine major
hospitals and 12 clinics, through a commercial infor-
mation system. All available databases were integrated in a
Microsoft SQL database in the data warehouse at the
MOH. Despite the fact that all hospitals and most clinics
had an electronic information system by the end of 2012,
data are not always routinely entered and reported
consistently for all facilities due to inadequate resources.
During the data cleaning process, we removed 620
individuals’ observations for having clinical records over
90 days after documented death. Because some clinics
keep ART drug refill records separately to PIMS, the drug
regimens from 68 facilities were not available for this
analysis. The individuals without documented antire-
troviral regimens or no baseline CD4þ cell counts
dropped from regression models, which restricted the
sample to 94 166 (see Fig. 1). Observations from 86 845
were included in a sensitivity analysis where individuals
initiated in 2012 and 2013 are removed from the original
model. These individuals were excluded because they
might have had a different pattern of mortality and loss to
follow-up (LTFU) than those who initiated earlier [6].
The primary outcome measure for this analysis was
mortality. For this analysis, ‘documented death’ referred
to a death event recorded in the database. Some deaths
were not reported to the Masa Programme, leading those
individuals to be marked as LTFU. LTFU here is defined
by no recorded clinical visits or prescription refills for 90
days after a missed clinical visit/refill. Baseline CD4þ cellcounts were defined as any CD4þ cell count reported in
the 90 days before treatment initiation, only if there was
not a recorded baseline CD4þ cell count.
Statistical analysis
We used a person-years (P-Y) approach to analyse event
rates. Follow-up time was measured from the date of
ART initiation until death, or to the date of the last visit
to the clinic. For the patients who did not start ART
immediately after enrolment, only their post-ART
follow-up time entered the analysis.
We used marginal structural modelling to estimate
predictors of death among HIV patients on ART. We
used this technique to address the complex issue of LTFU
and prevent bias in interpreting the results [7,8]. Using
observed variables, this approach allows us to derive a
weight for each individual in each quarter, i.e., the inverse
probability of remaining in the study in that interval [9].
Following the literature, the stabilized version of inverse
probability of LTFU was estimated as a ratio of two
predicted probability from two pooled logistic regression
models. To correct for auto-correlation in the panel
setting, we clustered the standard errors at patient level;
and to deal with the clustering effect at district-level,
we included dummy variable for each district in the
models as fixed effect. In the model for the numerator
only the baseline covariates were included, while for the
denominator the logistic model was fitted with the
baseline and time-varying covariates [10].
In the regression model we used all the patient-level
demographic and medical variables captured for the
majority of the patients in the database. The variables
include age, sex, CD4þ cell count, and treatment regimen
at baseline. We did not include viral load data due to poor
data quality. Additionally, treatment initiation calendar
year was included to capture the potential effect of
guideline changes. Medication regimen at each quarter
was added as the time-varying variable.
To evaluate the robustness of the findings, we performed a
sensitivity analysis by removal of the observations from
the last 2 years (2012 and 2013) due to low numbers of
observations and documented deaths, and the potential of
these patients to have different patterns of mortality and
LTFU. We also restricted the model to patients who had
only been on treatment for less than a year, to see how
these patients may differ from the overall model results.Results
In the database used for this analysis, the number of
patients ever initiated ART in the Masa Programme
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Total number of patients, age 18 years and over,in dataset
with documented initiation dates (n = 226 650) 
Excluded Individuals
620 removed for having clinical observations more
than 90 days after documented death 
Adults patients included in analysis of survival (n = 226 330)
Adults patients included in predictors of mortality analysis
(n = 94 166)  
Excluded from the longitudinal regression analysis
85 538 no drug regimen
28 057 no baseline CD4+
7673 no date of birth 
3640 inconsistent drug regimens
3516 only pre-treatment follow-up
3468 LTFU after the first visit 
2 too few observations in Mabutsane district
Fig. 1. Description of Botswana National Antiretroviral Treatment Programme data.increased from 3206 in 2002 to 226 030 by October 2013
[These are the numbers of enrollees in the programme
whose records were captured electronically and after data
cleaning to remove observations with poor data quality].
The largest increase in initiation was in 2006, after which
the increasing rate of ART initiation gradually declined.
Table 1 contains descriptive statistics for the patients in
the Masa programme. Of these patients, 82% had a
baseline CD4þ cell count value in the database. A high
percentage of the study population was female (62%), and
median age at baseline was 33 for women [interquartile
range (IQR) 28–40] and 38 for men (IQR 32–45).
The median baseline CD4þ cell count was 147 cells/ml
(IQR 79–200). Majority of the patients (72%) have a
CD4þ cell count between 50 and 250 cells/ml, whereas
15% of patients initiated with a very low baseline CD4þ
cell count (<50 cells/ml). As a result of changing the
CD4þ cell count threshold for ART eligibility from 200
to 250 cells/ml in 2008, 18 777 patients with CD4þ cellcount between 200 and 250 cells/ml were able to start
treatment earlier. Median baseline CD4þ cell count
increased from 88 cells/ml (IQR 38–156) in 2002, to
258 cells/ml (IQR 147–337) in 2013.
A total of 15 150 (7%) patients died during 2002–2013, of
whom 9670 (64% of total deaths) died in the first year
after treatment initiation, of those who died in the first
year, 6261 (65% of deaths in the first year) died in the first
3 months. We found that the proportion of deaths in the
first week, first 3 months, and first year of treatment have
been decreasing over the 12 years of the Masa Programme
(see Fig. 2). In 2002, 229 people (7%) initiating ART died
in their first year of treatment, whereas in 2012, 340
people (2%) initiating ART died in their first year.
The average mortality rate was 2.06 deaths per 100 P-Y
over a total follow-up time of 687 759 P-Y. Mortality rate
was greatest in the first year of follow-up at 5.30 deaths
per 100 P-Y [95% confidence interval (CI) 5.19–5.41]
and decreased to 1.01 deaths per 100 P-Y (95% CI 0.98–
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Table 1. Baseline patient characteristics for patientsa initiating antiretroviral treatment in the Botswana National HIV/AIDS Treatment
Programme, 2002–2013.
Continuous variables Median IQR Total
Number of clinic visits 5 2–10 226 030
Months of follow-up 37 11–75 202 818
Age (years) 35 29–42 214 804
Baseline CD4þ 147 79–200 185 805
Indicator variables No. of patients % of study population
Women 138 653 61.8 224 310
Year of initiation 226 030
2002–2007 121 509 53.8
2008–2013 104 521 46.2
First-line ART regimen (NNRTI or PI) 128 450
Nevirapine 52 346 40.8
Efavirenz 73 655 57.3
Lopinavir 2449 1.9
First-line ART regimen (NRTI) 128 450
Zidovudine 92 542 72.1
Stavudine 9605 7.5
Tenofovir 26 303 20.5
ART regimen switch 129 946
NRTI switch 12 186 9.4
NNRTI switch 7085 5.5
PI switch 3832 3.0
ART, antiretroviral therapy; IQR, interquartile range.1.04), after the first year on ART. Within the first year of
treatment, the first 3 months shows highest mortality rate
at 11.79 deaths per 100 P-Y (95% CI 11.49–12.11), but
the rate decreases to 1.88 deaths per 100 P-Y (95%
CI 1.75–2.03) between 9 and 12 months after treatment
initiation. Moreover, the rate during the first 3 months on
ART decreased over the years of the programme. The
mortality rate in the first 3 months of treatment was 14.29
deaths per 100 P-Y (95% CI 13.41–15.23) in 2005 and
decreases over time to 6.34 deaths per 100 P-Y (95%
CI 5.57–7.22) in 2012 (see Fig. 3).
Median follow-up time was 37 months (IQR 11–75).
The median duration of follow-up for patients who were
LTFU was 24 months (IQR 8–47), compared with a
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Fig. 2. Distribution of yearly deaths by duration of treatment.not lost. The incidence of LTFU was 12.47 per 100 P-Y
(95% CI 12.38–12.55) overall. However, LTFU rate was
14.87 per 100 P-Y (95% CI 14.68–15.05) for patients in
their first year of ART treatment, with the lowest rate
between 3 and 6 months [13.33 per 100 P-Y (95% CI
12.98–13.69)], and highest between 9 and 12 months
[18.18 per 100 P-Y (95% CI 17.75–18.61)]. The lowest
rate of LTFU by year of initiation was 7.74 per 100 P-Y
(95% CI 7.52–7.97) in 2003, and the highest rate of
LTFU was 22.45 per 100 P-Y (95% CI 21.75–23.18)
for those initiating in 2011. Some patients who were
transferred were considered LTFU, as there was not
enough data to match their records across facilities. There
were 51 548 patients who transferred facilities since 2002,
and only 14 922 of transferred patients had their records
linked.2010 2011 2012 2013
More than 1 year
3 months - 1 year
1 week - 3 months
Less than 1 week
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Fig. 3. Mortality rate in the first year after treatment initiation.For 128 450 patients whose first-line ART medication
was available and consistent in the Masa Programme
database [Some of the ART drug data was removed
because of inconsistency, e.g. if the medical records
indicated that a patient was on tenofovir and zidovudine
at the same time.], zidovudine and tenofovir were the
main nucleoside/nucleotide reverse-transcriptase inhibi-
tors (NRTIs) used, with 72% of people starting with
zidovudine compared with 21% on tenofovir [Following
the 2008 change in the guideline, tenofovir replaced
zidovudine as the first-line NRTI in Botswana.] and the
remainder of patients, 7%, on stavudine. Since almost
all patients who started on zidovudine also received
lamivudine, and those who started on tenofovir also
receive emtricitabine either separately or as a combi-
nation, Combivir and Truvada (or Atripla), respectively,
we just mention zidovudine and tenofovir throughout
this article. The population on non-nucleoside reverse-
transcriptase inhibitors (NNRTIs) were split between
efavirenz and nevirapine, 57 and 41%, respectively, with
the remainder of patients, 2%, starting on the protease
inhibitor (PI), lopinavir.
Regression analysis
Table 2 presents the results of the marginal structural
model (weighted to compensate for the patients LTFU),
an analysis of patients in their first year of treatment and
the sensitivity analysis. Comparing three main first-line
NRTI medications in Botswana National ART Pro-
gramme, namely zidovudine, tenofovir and stavudine, we
found that the mortality odds ratio among patients
starting on zidovudine was 1.2 times that of tenofovir(95% CI 1.1–1.3). Stavudine-containing regimens were
associated with 4.9 times the odds of mortality rate
compared with tenofovir (95% CI 4.3–5.6). Those on
efavirenz had a slightly higher rate of mortality when
compared with those on nevirapine with an odds ratio
(OR) of 1.12 (95% CI 1.03–1.2). The odds of mortality
for those who switched NRTI or NNRTI are less, as
compared with those who stayed with the original
prescription.
Those who initiated ART after 2008 had lower odds of
mortality compared with those who initiated before
2008. Our model predicted a lower risk of mortality for
women [OR 0.64, (95% CI 0.60–0.69)], compared with
men. The odds of death increased after the age of 40.
Additionally, having a baseline CD4þ cell count below
100 increased the odds of death by 1.89 times (95%
CI 1.79–1.99).
Model 2, including only those that have been on
treatment for less than a year, shows similar results to the
main model with a few key differences. The odds of
mortality with zidovudine and stavudine was higher
compared with tenofovir, whereas patients on efavirenz
were less likely to die compared with those on nevirapine
[OR 0.87 (95% CI 0.79–0.97)]. Having a baseline CD4þ
cell count of less than 100 cells/ml has a stronger effect in
this model than in the model containing all individuals
[OR 2.56 (95% CI 2.37–2.77)]. In Model 3, only
one estimate changed after removing those initiating in
the last 2 years, specifically the inferiority of zidovudine
became statistically insignificant.
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Table 2. Predictors of mortality regression results and sensitivity analysis.a,b,c
Model 1: all patients
Model 2: including only patients
in their first year of treatment
Model 3: excluding those
initiating in 2012 and 2013
Adjusted OR 95% CI Adjusted OR 95% CI Adjusted OR 95% CI
Tenofovir 1 1 1 1 1 1
Zidovudine 1.19MM [1.06, 1.34] 2.04MMM [1.72, 2.42] 1.06 [0.95, 1.20]
Stavudine 4.91MMM [4.30, 5.62] 6.47MMM [5.33, 7.86] 4.400MMM [3.84, 5.04]
Nevirapine 1 1 1 1 1 1
Efavirenz 1.12MM [1.03, 1.20] 0.88M [0.79, 0.98] 1.166MMM [1.08, 1.26]
Lopinavir 0.94 [0.73, 1.22] 0.32MMM [0.19, 0.54] 0.99 [0.77, 1.29]
Ever switched NRTI 0.26MMM [0.23, 0.29] 0.15 [0.02, 1.01] 0.26MMM [0.23, 0.29]
Ever switched NNRTI 0.58MMM [0.51, 0.66] 1 [1,1] 0.57MMM [0.50, 0.66]
Initiation year >2008 0.75MMM [0.68, 0.83] 0.63MMM [0.53, 0.73] 0.77MMM [0.69, 0.85]
Female 0.66MMM [0.62, 0.71] 0.77MMM [0.70, 0.84] 0.68MMM [0.64, 0.74]
Age >40 1.21MMM [1.14, 1.28] 1.32MMM [1.22, 1.44] 1.19MMM [1.12, 1.26]
Baseline CD4 < 100 1.92MMM [1.82, 2.02] 2.57MMM [2.38, 2.78] 1.87MMM [1.77, 1.97]
Follow-up month 0.92MMM [0.92, 0.93] 0.95MMM [0.94, 0.96] 0.92MMM [0.92, 0.93]
Sample size 996 770 43 121 973 925
CI, confidence interval; OR, odds ratio. Level of statistical significance: M0.1; MM0.05; MMM0.001.
aModels are run with a cubic knot spline and with health district fixed effects (not reported here).
bEach variable is an indicator variable except for follow-up month, which is a continuous variable.
cModels are weighted to account for loss to follow-up.Discussion
This study is the first comprehensive analysis of the trends
and determinants of mortality for over 200 000 patients in
an African National ART Programme. We found low
rate of mortality and high rate of LTFU after treatment
initiation, which was similar to other African cohorts
[11]. The crude mortality rate was 2.06 deaths per 100
P-Y, which is lower than a Ghanaian cohort, with
2.9 deaths per 100 P-Y [12], and a Rwandan cohort with
3.7 deaths per 100 P-Y [13], and higher than a similar
cohort in South Africa, with 1.08 deaths per 100 P-Y
[14]. All of these estimates are substantially lower than
the 16.1 deaths per 100 P-Y found in a Zambian cohort
[15].
In this study, like similar studies in sub-Saharan Africa
[16], more than 64% of deaths happened in the first year
after treatment initiation. However, the percentage of
individuals who died in their first year of treatment has
been steadily decreasing over the years, from 7 to 2% of
those initiating ART during 2002–2012. Our findings
are similar to a study evaluating seven programmes in
South Africa, where 12-month mortality decreased to 6%
in 2007 from 9% in 2002 [17]. This suggests that patients
are now remaining in the programme longer, and can be
successfully treated, although early mortality is still a
major concern.
Crude mortality rate in the first 3 months of ART
initiation is at 11.8 deaths per 100 P-Y, which is
significantly lower than estimates found in other studies.
In a South African cohort, followed from 2007 to 2012,
the crude mortality rate in the first 3 months of ARTwas
19.4 per 100 P-Y. The mortality rate during the first
3 months of treatment in Zambia and China was found tobe 26 and 22.6 deaths per 100 P-Y respectively [15,18].
Differences in follow-up period and a significant drop in
mortality rates across the 12 years of the programme may
explain the differences in these estimates.
A notable outcome of the rapid scaling-up of the
Botswana National ART programme from 2002 to 2013
was its success in decreasing mortality in the first 3 months
after treatment initiation from more than 20 deaths per
100 P-Y in 2002, to six deaths per 100 P-Y in 2012. A
similar pattern, but higher rates are found in a study in
South Africa, where mortality rates in the first 3 months
dropped from 21.4 per 100 P-Y (95% CI 18.3–24.8)
in 2004–2005 to 9.0 per 100 P-Y (95% CI 7.3–11.0) in
2011–2012 [19]. It is likely that the high rates of LTFU
in the third and fourth quarter after ART initiation in
Botswana are causing us to underestimate mortality rates
6 months after ART initiation. Although this trend is
often seen in similar studies in resource-limited settings,
the mortality rates in Botswana remain a great deal lower,
even when mortality rates are restricted to the same years
of follow-up [15,18]. Diminishing rate of mortality in the
first 3 months after treatment initiation in Botswana can
be partially explained by higher CD4þ cell counts at
treatment initiation and by replacing zidovudine with
tenofovir as the first-line regimen in 2008 [20].
Some patients in our study may fulfil the definition of
LTFU because they were transferred, but their medical
records could not be linked due to differences in patient
identifiers or differences in reporting consistency at the
receiving facility. Some patients may have died without
being recorded in the electronic system. Using a method
to trace patients, a study of 524 patients in Botswana in
early 2003 showed that more than half of the 68 patients
originally deemed to be LTFU were confirmed to be
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are LTFU in our study have probably died [21].
Some of the LTFU can be explained by poor data quality.
Some LTFU patients were probably still receiving care,
but the facility failed to fill in the medical record
electronically. Some facilities reported only demographic
data and failed to report the laboratory results or
prescription drug regimens of patients. Even the data
reporting quality, or lack thereof, at certain facilities was
not consistent, and fluctuated over time. Improving the
data collection process should be a priority in the
Masa Programme.
Although average retention across districts in Botswana
has improved over time, many patients did not receive
medical care at recommended intervals. Retention in care
for those on ART is essential as they need to ensure
uninterrupted receipt of ART, prevention and treatment
of opportunistic infections, as well as continued clinical
and laboratory monitoring to detect drug-related toxicity
or treatment failure [22].
In this analysis, tenofovir was found to be associated with
substantially lower rate of mortality compared with
zidovudine and stavudine, which have higher rates of
toxicity [23]. Our findings are in line with the results of
other studies in the literature. In randomized trials,
tenofovir has demonstrated comparable or greater efficacy
compared with other first-line regimens, such as
zidovudine and stavudine [24].
The results presented show that efavirenz was slightly
inferior to nevirapine. In the sensitivity analysis, the result
was reversed, which may confirm the findings of previous
studies concluding there was no difference in efficacy
between the two drugs [25]. Although we are not able to
offer an explanation for the inferiority of efavirenz in the
main model, we can stipulate that there were unmeasured
confounders associated with prescription of NNRTIs in
Botswana that contributed to inferior outcomes for
efavirenz in this study.
Being highly immunosuppressed at the initiation of
therapy, with a baseline CD4þ cell count less than
100 cells/ml, was a strong predictor of mortality, as has
been shown in several similar studies [26,27]. Consistent
with the literature, higher CD4þ levels in this population
were positively correlated with survival.
Consistent with similar studies [15,28], individuals who
were male and older individuals were more likely to die in
the Masa Programme. There is a range of explanations for
gender difference in mortality on ART. Given that in our
regression model we accounted for the baseline CD4þ
level and duration of follow-up, one probable explanation
for lower mortality among women would be superior
adherence to ART, which we could not control for in ourmodel. In Botswana, like other studies in similar settings,
women’s better outcome can be associated with better
treatment adherence and health-seeking behaviour
[29–31]. Moreover, the cause of death in the database
is unknown, and some of these patients may have died of
non-AIDS defining conditions [32]. There is higher
mortality among men in general as men are more likely to
have risk factors for respiratory and cardiovascular disease,
and to be involved in motor vehicle accidents, homicide,
and suicide [33]. It is also important to note that older
individuals are more likely to die from other causes
unrelated to AIDS, e.g., cardiovascular disorders,
cerebrovascular accidents, and cancer, which may
contribute to higher mortality in this age. Therefore,
we cannot necessarily establish a correlation between the
HIV infection or treatment status and higher mortality
rate among the male or older patients.
Limitations
There are limitations to this study that should be
acknowledged. The main limitation is the potential for
missing death data due to inconsistent reporting;
however; we tried to account for this through our
analysis of patients lost to follow-up, specifically in the
regression model, by using marginal structural modelling
to correct for bias that it may have introduced. There is
also missing data for ART regimen and CD4þ; however,
it is less troubling as causes of missing data may include
understaffing, lack of adequate training, and poor data
recording due to lack of infrastructure. We could not find
any evidence indicating missing data and incorrect entries
may have introduced selection bias to this analysis, or
have limited the generalizability of these findings, unless a
correlation between documentation and quality of care is
assumed. Strengths of this study include our large sample
size and repeated measures over 12 years of the Masa
Programme.
Conclusions
Our analysis of the Botswana National ART Programme
highlights areas of success and areas needing improve-
ment. The success of the programme can be explained, in
part, by the fact that the system adjusted itself through
revising the treatment guidelines, earlier identification of
the patients in the course of their infection, better trained
personnel and an improved health information system [5].
The programme succeeded in reducing overall as well as
early mortality (12 months and 3 months after treatment
initiation). Although earlier HIV diagnosis and ART
initiation at higher CD4 can improve survival, the
findings of this study call for interventions to target
reduction in early mortality and in keeping patients
engaged in care. Last but not least, the study emphasizes
the critical role of high-quality, routine data collection
and reporting, for epidemiological studies and day-to-day
clinical practice.
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